Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunosuppression, ongoing clinical trials].

J Rivalan1

  • 1CHU de Rennes.

Presse Medicale (Paris, France : 1983)
|October 2, 2001
PubMed
Summary

Humanized monoclonal antibodies and mTOR inhibitors like sirolimus offer improved immunosuppression with fewer side effects. Research explores their use in reducing calcineurin inhibitor dosage and corticosteroid dependence in transplant recipients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

[Acquired copper deficiency myelopathy].

Revue neurologique·2010
Same author

Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression.

Transplantation·2001
Same author

[Natural history of vascular ports for hemodialysis after renal transplantation].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2001
Same author

Contribution of 99Tcm-DMSA scintigraphy to aetiological diagnosis in renal transplant recipients with impaired renal function.

Nuclear medicine communications·2000
Same author

[Polyradiculoneuropathy in an adult with primitive hyperoxaluria].

Revue neurologique·2000

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation

Context:

  • Humanized monoclonal antibodies (e.g., anti-CD3, anti-CD52) demonstrate improved tolerance and duration of action.
  • Sirolimus and everolimus, while similar, present dose-dependent side effects but allow for reduced calcineurin inhibitor dosages.
  • Corticosteroid-related complications, especially bone issues, persist even at low doses in transplant recipients.

Purpose:

  • To review advancements in immunosuppressive therapies, focusing on monoclonal antibodies and mTOR inhibitors.
  • To discuss strategies for minimizing side effects associated with corticosteroids and calcineurin inhibitors.
  • To highlight emerging immunosuppressor classes, including anti-adhesion molecules and co-stimulation blockers.

Summary:

  • Humanized anti-CD3 antibodies, including those targeting CD52, are well-tolerated and are being investigated in combination therapies.
  • Sirolimus and everolimus offer immunosuppression with manageable side effects, facilitating calcineurin inhibitor reduction and corticosteroid withdrawal.
  • Complete corticosteroid withdrawal is challenging due to increased acute rejection risk, necessitating alternative strategies.

Impact:

  • These therapeutic advancements aim to improve long-term outcomes and quality of life for transplant recipients.
  • Optimizing immunosuppression regimens can reduce treatment-related toxicities and complications.
  • Future immunosuppressive strategies focus on novel targets like adhesion molecules and T-cell activation pathways.

Related Experiment Videos